Clinical trials: Recurrent Bacterial Vaginosis
Bacterial Vaginosis
Flourish HEC to Prevent Recurrence of BV
In a population of women with heightened vulvovaginal sensitivity and recurrent bacterial vaginosis (BV), the use of the Flourish HEC Vaginal Care System is being tested for prevention of BV recurrence over six months of use.
- Trial name
- NCT05386147
- Testing
- Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vaginal Biome Science
Bacterial Vaginosis, Recurrence
Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis
We are trying to determine if Oral Metronidazole with Lactobacillus Vaginal Suppositories is better than Oral Metronidazole in Preventing the Recurrence of Bacterial Vaginosis
- Trial name
- NCT03099408
- Testing
- Metronidazole Oral, "Metronidazole" and "Lactobacillus"
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University Shenzhen Hospital
Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina
The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
The aim of the study is to investigate the efficacy of Fluconazol versus L-Mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. Vaginal swabs will be analyzed after 1, 6 and 12 months.
- Trial name
- NCT05367089
- Testing
- Fluconazole, L-Mesitran
- Where
- 2 sites in Netherlands
- Volunteers
- 252 people
- Sponsor
- Maastricht University Medical Center
Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina
Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis
The purpose of this study is to compare the efficacy of Flucanzol versus L-mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. The investigator will look at vaginal swabs after 1, 6 and 12 months.
- Trial name
- NCT04626258
- Testing
- Fluconazole, L-Mesitran
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Bacterial Vaginosis
Photobiomodulation With Blue LED in Recurrent Bacterial Vaginosis
Introduction: Bacterial vaginosis (BV) is the most prevalent vaginal dysbiosis in women of reproductive age and is associated with adverse gynecological and obstetric outcomes; therefore, its diagnosis and appropriate treatment…
- Trial name
- NCT07835815
- Testing
- Metronidazole, Blue Light-Emitting Diode (LED)
- Volunteers
- 40 people
- Sponsor
- Patricia Lordelo
Recurrent Bacterial Vaginosis
Randomized Controlled Trial of Treatment of Male Partners of Women With BV
Male partners of womoen with recurrent bacteria vaginosis are randomized to treatment with metronidazole or placebo to compare the rates of recurrent BV in the women
- Trial name
- NCT02209519
- Testing
- Metronidazole (male partner), Placeob (male partner)
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- University of Alabama at Birmingham
Bacterial Vaginosis
The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis
Purpose of the proposed research is to determine the impact of probiotic yogurt supplemented with Lactobacillus rhamnosus (Fiti) compared to regular yogurt on the well-being of women living with HIV.
- Trial name
- NCT01258556
- Testing
- Yogurt supplemented with L. rhamnosus fiti, Yogurt not supplemented with a probiotic strain.
- Where
- Tanzania
- Volunteers
- 150 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03561701)
- Testing
- Oteseconazole (VT-1161)
- Where
- 14 sites in United States
- Volunteers
- 425 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Recurrent Bacterial Vaginosis (BV)
Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)
The purpose in this clinical study is to determine the efficacy of SPL7013 Gel for the prevention of recurrence of bacterial vaginosis.
- Trial name
- NCT01437722
- Testing
- 1% SPL7013 Gel, 3% SPL7013 Gel
- Volunteers
- 205 people
- Sponsor
- Starpharma Pty Ltd
Recurrent Bacterial Vaginosis
Probiotics as an Adjunct to Antibiotics for Recurrent Bacterial Vaginosis
This randomized clinical trial aims to compare the recurrence of bacterial vaginosis (BV) in women receiving probiotics alongside antibiotic treatment versus women receiving antibiotic treatment alone.
- Trial name
- NCT07893782
- Testing
- Probiotic Combination Cap/Tab
- Where
- Pakistan
- Volunteers
- 70 people
- Sponsor
- Nishtar Medical University
Vulvovaginal Candidiasis
Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
This study evaluates the effect of a multi-strain probiotic on the risk of recurrence and severity of symptoms in females with recurrent vulvovaginal candidiasis (R-VVC).
- Trial name
- PROVELIA (NCT06480604)
- Testing
- Probiotic
- Where
- 6 sites in India
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Recurrent Vulvovaginal Candidiasis
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
In this study, the pentavalent bioconjugate candidate vaccine (Candi5V) against Candida will be tested to obtain first-time-in-human (FTIH) data on its safety, immunogenicity, and preliminary efficacy in women with recurrent…
- Trial name
- NCT06190509
- Testing
- Vaccine
- Where
- 7 sites in Belgium, Poland
- Volunteers
- 251 people
- Sponsor
- LimmaTech Biologics AG
Recurrent Bacterial Vaginitis
Vaginal Flora for Treatment of Bacterial Vaginosis
Bacterial vaginosis (BV) is the most common vaginal infection in women. It is caused by a vaginal bacterial imbalance. Treatment with antibiotics is the standard of care but there is a high rate of recurrence.
- Trial name
- VFT (NCT02236429)
- Testing
- vaginal flora transplant
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Hadassah Medical Organization
Recurrent Vulvovaginal Candidiasis
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
VT-1161 is a novel, oral inhibitor of fungal lanosterol demethylase (CYP51). In vitro and in vivo pharmacology studies have demonstrated that VT-1161 is highly active against Candida albicans and also non-albicans Candida species…
- Trial name
- NCT02267382
- Testing
- VT-1161
- Where
- 32 sites in United States
- Volunteers
- 254 people
- Sponsor
- Viamet
Vulvovaginal Candidiasis
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability and humoral and cellular immune response over a 12-month period after receiving one dose of either the NDV-3A…
- Trial name
- NCT01926028
- Testing
- NDV-3A, NDV-3
- Where
- 20 sites in United States
- Volunteers
- 188 people
- Sponsor
- NovaDigm Therapeutics, Inc.
Recurrent Vulvovaginal Candidiasis
Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis
The objective of this study is to evaluate the efficacy of the consumption of the one probiotic strain in the prevention of new vaginal candidiasis events in women with recurrent vaginal candidiasis.
- Trial name
- NCT04639544
- Testing
- Lactobacillus strain
- Where
- Spain
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Bacterial Vaginoses
Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis
Vaginal Microbiome Transplantation (VMT) may be beneficial in treating the most severe cases of recurrent and antibiotics-nonresponsive cases of BV.
- Trial name
- NCT04517487
- Testing
- Vaginal Microbiome Transplantation (VMT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
Vulvovaginal Candidiasis
Comparison of Boric Acid vs. Terconazole in Treatment of RVVC
Vulvovaginal candidiasis (VVC) caused by Candida species, predominantly C. Albicans is considered one of the most common infections of the lower female genital tract affecting 75% of women at least once in their lifetime.
- Trial name
- NCT04208555
- Testing
- Boric Acid Vaginal Suppository, Terconazole Vaginal Suppository
- Volunteers
- 76 people
- Sponsor
- Hatem AbuHashim
Recurrent Vulvovaginal Candidiasis
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute vulvovaginal candidiasis (VVC) in the past 12 months.
- Trial name
- ultraVIOLET (NCT03840616)
- Testing
- Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule
- Where
- 33 sites in United States
- Volunteers
- 219 people
- Sponsor
- Mycovia Pharmaceuticals Inc.